Safety and Efficiency Study of Valproic Acid In HAM/TSP
Reversible acetylation of the histone tails plays an important role in the control of specific gene expression. Mounting evidence has established that histone deacetylase inhibitors such as Valproic Acid (VPA)selectively induce cellular differentiation and apoptosis in variety of cancer cells. In a single-center, one year open-label trial, 19 HAM/TSP patients were treated with oral doses of VPA...
Brief Summary
Official Title: “Open Label Study of the Clinical and Laboratory Effects of Valproic Acid In HAM/TSP”
Reversible acetylation of the histone tails plays an important role in the control of specific gene expression. Mounting evidence has established that histone deacetylase inhibitors such as Valproic Acid (VPA)selectively induce cellular differentiation and apoptosis in variety of cancer cells. In a single-center, one year open-label trial, 19 HAM/TSP patients were treated with oral doses of VPA (20mg/Kg/day). Primary end-points were the therapeutic safety and the effect on HTLV-1 proviral load (a significant and sustained decrease was expected). Secondary end-point was the neurological status before and after one-year treatment.
- Study Type: Interventional
- Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention(s) in this Clinical Trial
- Drug: Valproic Acid
- Valproic acid by oral route (20mg/Kg/day) during one year.
Outcome Measures for this Clinical Trial
Primary Measures
- Clinical and laboratory safety of Valproic Acid in HAM/TSP. Effect on HTLV-1 proviral load in peripheral blood mononuclear cells.
- Time Frame: one year
- Time Frame: one year
Secondary Measures
- Neurological outcome.
- Time Frame: one year
- Time Frame: one year
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- HAM/TSP patients diagnosed on WHO criteria
- Obtained informed consent.
Exclusion Criteria:
- Patients with hepatic or nephrologic disease
- Valproic Acid allergy
- Pregnancy.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 80 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: University Hospital Pierre Zobda-Quitman Other
Overall Clinical Trial Officials and Contacts
Stephane OLINDO, MD Principal Investigator University Hospital Pierre Zobda-Quitman, Fort de France
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00519181
Study ID Number: PHRC-SO-2006-17
ClinicalTrials.gov Identifier: NCT00519181
Health Authority: France: Ministry of Health
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00519181
